Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

Affiliations

¹ Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
² Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Editorial

Anthonie J van der Wekken et al. J Thorac Dis. 2018 Jul.

. 2018 Jul;10(Suppl 18):S2130-S2132.

doi: 10.21037/jtd.2018.06.45.

¹ Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
² Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. Erratum in: N Engl J Med 2011;364:588. 10.1056/NEJMoa1006448 - DOI - PMC - PubMed
1. van der Wekken AJ, Pelgrim R, 't Hart N, et al. Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2017;23:4251-8. 10.1158/1078-0432.CCR-16-1631 - DOI - PubMed
1. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28. 10.1016/S1470-2045(14)70362-6 - DOI - PubMed
1. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73. 10.1158/2159-8290.CD-13-0846 - DOI - PMC - PubMed
1. Cui JJ, Zhai D, Deng W, et al. TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants. Eur J Cancer 2016;69:S32 10.1016/S0959-8049(16)32675-2 - DOI